Abstract:Importance Depression is associated with alterations in blood immuno-metabolic biomarkers, but it remains unclear whether these alterations are limited to select measures or represent broader patterns and can predict depression diagnosis. Objective To examine immuno-metabolic biomarker changes in depression, pattern of effect at the symptom and symptom-dimension level, and prediction of depression diagnosis. Design, Setting, and Participants Case-control and cohort-wide analyses of ICD-10 depression, depressive and anxiety symptoms based on up to N=4161 participants (2363 female) aged 24 years from the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort. Exposures Blood-based immunological and metabolic biomarkers (n=93) comprising inflammatory proteins, cell count, lipids, hormones, and metabolites. Main Outcomes and Measures ICD-10 diagnosis of depression, 11 individual depressive and anxiety symptoms, and four domain scores were used as outcomes. Confounders included sex assigned at birth, body mass index, smoking, and alcohol use. Results After adjusting for potential confounders and multiple testing, depression was associated with changes in concentrations of specific immuno-metabolic markers (IL-6, CDCP1, neutrophil count, and insulin), and greater number of extreme-valued inflammatory markers. We identified three distinct affective symptom-related biomarker clusters, including one comprising inflammatory cytokines, chemokines and cells which was positively associated with somatic and mood symptoms, and one comprising liver-related biomarkers which was negatively associated with anxiety symptoms. Then using Partial Least Squares regression we identified two latent variables that capture the biomarker-symptom associations (Component 1: Somatic-Depressive-Inflammation and Component 2: Anxiety-Hepatic). Higher Component 1 score was associated with higher depressive symptom severity consistently over subsequent five years. Immuno-metabolic biomarkers performed poorly in predicting ICD-10 depression (0.569 Balanced Accuracy). However, within depression cases the addition of immuno-metabolic biomarkers improved the prediction of depression with high levels of mood (0.720 Balanced Accuracy) or anxiety symptoms (0.636 Balanced Accuracy). Conclusion and Relevance Depression is associated with disruption in immuno-metabolic homeostasis. Specific patterns of immuno-metabolic biomarkers are associated with differing subsets of affective symptoms, which are potentially relevant for poor depression prognosis. Immuno-metabolic biomarkers improve predictions of high levels of mood symptoms within people with depression, highlighting the symptom-level heterogeneity of depression and opportunities for immuno-metabolic biomarker-based subtyping, prediction, and targeted intervention.

The recurrence of illness (ROI) index is a key factor in major depression that indicates increasing immune-linked neurotoxicity and vulnerability to suicidal behaviors

Relationship of insight to neurocognitive function and risk of recurrence in depression: A naturalistic follow-up study

T cell activation and lowered T regulatory cell numbers are key processes in severe major depressive disorder: Effects of recurrence of illness and adverse childhood experiences

Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials

Lower Nerve Growth Factor Levels in Major Depression and Suicidal Behaviors: Effects of Adverse Childhood Experiences and Recurrence of Illness

A further examination of growth factors, T helper 1 polarization, and the gut microbiome in major depression: Associations with reoccurrence of illness, cognitive functions, suicidal behaviors, and quality of life

Tumor markers and depression scores are predictive of non-suicidal self-injury behaviors among adolescents with depressive disorder: A retrospective study

Immunological correlates of suicidality among adolescents with internalizing symptoms

Blood Immuno-metabolic Biomarker Signatures of Depression and Affective Symptoms in Young Adults

Towards a major methodological shift in depression research by assessing continuous scores of recurrence of illness, lifetime and current suicidal behaviors and phenome features

Transcriptomic profiles in major depressive disorder: the role of immunometabolic and cell-cycle-related pathways in depression with different levels of inflammation

Major depressive disorder, neuroticism, suicidal behaviors, and depression severity are associated with cytokine networks and their intricate interactions with metabolic syndrome

Intron retention as an excellent marker for diagnosing depression and for discovering new potential pathways for drug intervention

Neutrophil/lymphocyte, Platelet/lymphocyte, Monocyte/lymphocyte Ratios and Systemic Immune-Inflammation Index in Patients with Depression.

Relative value of novel systemic immune-inflammatory indices and classical hematological parameters in predicting depression, suicide attempts and treatment response

Intron retention can be an excellent marker for evaluating the depressed state and useful for discovering new pathways in the recovery of depression by a drug.

Investigation of peripheral inflammatory biomarkers in association with suicide risk in major depression

Self-blame-Selective Hyperconnectivity Between Anterior Temporal and Subgenual Cortices and Prediction of Recurrent Depressive Episodes

Higher atherogenic index of plasma is associated with increased major depressive disorder: insights from a nationally representative study

Increased inflammation and brain glutamate define a subtype of depression with decreased regional homogeneity, impaired network integrity, and anhedonia

Associations among serum markers of inflammation, life stress and suicide risk in patients with major depressive disorder